NO
NOTA.F Novartis AG
- Market cap
- EUR 272B
- P/E
- 31.9x
- P/B
- 8.10x
- ROE
- 27.3%
- Dividend yield
- 2.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NOTA.F undervalued?
Graham numberThe Graham number of Novartis AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novartis AG fundamental analysis
No fundamental analysis for Novartis AG yet.
Novartis AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade fo…
Full company profileNovartis AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novartis AG annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 49.4B | 50.1B | 53.2B | 48.7B | 49.9B | 52.9B | 51.8B | 46.7B | 51.7B | 56.7B | 58.0B |
| Gross Profit | 31.9B | 33.0B | 34.8B | 34.3B | 34.8B | 37.0B | 36.3B | 34.2B | 38.9B | 43.0B | 43.6B |
| Operating Income | 8.27B | 8.63B | 8.17B | 9.09B | 10.2B | 11.7B | 9.20B | 9.77B | 14.5B | 17.6B | 14.4B |
| EBITDA | - | 15.9B | 21.7B | 15.6B | 17.2B | 33.1B | 16.4B | 18.3B | 20.7B | 22.8B | 22.5B |
| Net Income | 6.71B | 7.70B | 12.6B | 11.7B | 8.07B | 24.0B | 6.96B | 14.9B | 11.9B | 14.0B | 10.2B |
| EPS | - | 3.32 | 5.46 | 5.18 | 3.58 | 11 | 3.28 | 7.27 | 6.05 | 7.33 | 5.38 |
| Balance Sheet | |||||||||||
| Total Assets | 130B | 133B | 146B | 118B | 132B | 132B | 117B | 99.9B | 102B | 111B | 117B |
| Total Liabilities | 55.2B | 58.9B | 66.9B | 62.8B | 75.4B | 64.0B | 58.0B | 53.2B | 58.1B | 64.4B | 79.6B |
| Shareholders' Equity | 74.8B | 74.2B | 78.6B | 55.5B | 56.6B | 67.7B | 59.3B | 46.7B | 44.0B | 46.1B | 37.2B |
| Cash & Short-term Investments | 7.01B | 8.86B | 13.3B | 11.1B | 9.66B | 12.4B | 7.52B | 13.4B | 11.5B | 11.4B | 8.87B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.5B | 12.6B | 14.3B | 13.6B | 13.7B | 15.1B | 14.2B | 16.0B | 17.6B | 19.1B | 20.1B |
| Capital Expenditure | 2.88B | 1.33B | 1.25B | 1.38B | 1.28B | 1.38B | 1.20B | 2.90B | 3.81B | 3.90B | 3.08B |
| Free Cash Flow | - | 9.88B | 10.9B | 11.4B | 11.1B | 12.1B | 11.6B | 13.1B | 13.8B | 15.2B | 17.0B |
| Ratios | |||||||||||
| ROE | 9.0% | 10.4% | 16.0% | 21.1% | 14.3% | 35.5% | 11.7% | 31.8% | 27.1% | 30.3% | 27.3% |
| ROA | 5.2% | 5.8% | 8.7% | 9.9% | 6.1% | 18.2% | 5.9% | 14.9% | 11.7% | 12.6% | 8.7% |
| Net Profit Margin | 13.6% | 15.4% | 23.7% | 24.1% | 16.2% | 45.4% | 13.4% | 31.8% | 23.1% | 24.7% | 17.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Novartis AG dividends
- Dividend yield
- 2.90%
- Forward dividend
- 4.15 EUR
- Payout ratio
- 55.9%
- Ex-dividend date
- Mar 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 7.82B | 4.10 | 55.9% |
| 2024 | USD 7.62B | 3.86 | 63.8% |
| 2023 | USD 7.26B | 3.55 | 48.9% |
| 2022 | USD 7.51B | 3.54 | 107.9% |
| 2021 | USD 7.37B | 3.30 | 30.7% |
| 2020 | USD 6.99B | 3.10 | 86.6% |
| 2019 | USD 6.65B | 2.93 | 56.6% |
| 2018 | USD 6.97B | 3.01 | 55.2% |
| 2017 | USD 6.50B | 2.80 | 84.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Novartis AG
- Insiders 0.01%
- Institutions 7.34%
- Public & others 92.65%
- Shares outstanding 1.89B
- Free float 1.84B
Novartis AG company profile
- Company name
- Novartis AG
- Ticker
- NOTA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 75,267
- Fiscal year end
- December
- Address
- Lichtstrasse 35, Basel, Switzerland, 4056
- Phone
- 41 61 324 11 11
- Website
- novartis.com
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG management
10- Dr. Vasant Narasimhan M.D.Chief Executive Officer · born 1976
- Mr. Victor BultoPresident of US · born 1978
- Dr. Patrick Horber M.D.President of International · born 1970
- Mr. Mukul MehtaChief Financial Officer · born 1973
- Dr. Steffen Lang Ph.D.President of Operations · born 1967
- Paul PenepentHead of Group Financial Reporting and Accounting
- Ms. Sloan SimpsonGlobal Head of Investor Relations
- Ms. Karen L. HaleChief Legal & Compliance Officer · born 1968
- Dr. Robert Kowalski Pharm.D.Chief People & Organization Officer · born 1968
- Mr. Evan BeckmanGlobal Head of Translational Medicine at Novartis Institute for BioMedical Research